Stanley Bergman Sells 10,785 Shares of Henry Schein (NASDAQ:HSIC) Stock

Henry Schein, Inc. (NASDAQ:HSIC) CEO Stanley Bergman sold 10,785 shares of the company’s stock in a transaction dated Friday, February 27th. The shares were sold at an average price of $81.20, for a total transaction of $875,742.00. Following the sale, the chief executive officer directly owned 309,092 shares of the company’s stock, valued at approximately $25,098,270.40. This represents a 3.37% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Henry Schein Trading Up 1.1%

HSIC opened at $82.39 on Friday. The firm has a market capitalization of $9.45 billion, a price-to-earnings ratio of 25.20, a price-to-earnings-growth ratio of 2.44 and a beta of 0.88. The company’s 50 day simple moving average is $77.85 and its two-hundred day simple moving average is $72.18. Henry Schein, Inc. has a 1-year low of $60.56 and a 1-year high of $89.29. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.38 and a quick ratio of 0.79.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings results on Tuesday, February 24th. The company reported $1.34 EPS for the quarter, beating the consensus estimate of $1.30 by $0.04. Henry Schein had a return on equity of 15.16% and a net margin of 3.02%.The firm had revenue of $3.44 billion during the quarter, compared to analysts’ expectations of $3.34 billion. During the same quarter last year, the firm earned $1.19 earnings per share. The business’s revenue for the quarter was up 7.7% on a year-over-year basis. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. Analysts expect that Henry Schein, Inc. will post 4.74 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the stock. Evercore upped their price objective on shares of Henry Schein from $83.00 to $90.00 and gave the company an “outperform” rating in a report on Wednesday, November 5th. Wells Fargo & Company increased their price target on shares of Henry Schein from $76.00 to $87.00 and gave the company an “equal weight” rating in a research note on Wednesday. Weiss Ratings reiterated a “hold (c)” rating on shares of Henry Schein in a research report on Monday, December 29th. Robert W. Baird set a $100.00 target price on Henry Schein and gave the company an “outperform” rating in a research report on Monday, February 23rd. Finally, Morgan Stanley increased their price objective on shares of Henry Schein from $58.00 to $61.00 and gave the stock an “underweight” rating in a research report on Wednesday. Six equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $85.58.

Institutional Investors Weigh In On Henry Schein

A number of hedge funds have recently bought and sold shares of the stock. CYBER HORNET ETFs LLC acquired a new position in shares of Henry Schein during the second quarter worth about $25,000. MUFG Securities EMEA plc purchased a new position in Henry Schein in the second quarter worth approximately $27,000. Flagship Harbor Advisors LLC acquired a new position in Henry Schein during the 4th quarter worth approximately $30,000. Federated Hermes Inc. purchased a new stake in shares of Henry Schein in the 4th quarter valued at approximately $32,000. Finally, Los Angeles Capital Management LLC acquired a new stake in shares of Henry Schein in the 4th quarter valued at $37,000. Institutional investors and hedge funds own 96.62% of the company’s stock.

More Henry Schein News

Here are the key news stories impacting Henry Schein this week:

• Positive Sentiment: Reported quarterly results topped expectations (better EPS and revenue growth), which reinforces momentum in the stable dental market and was a primary driver for the stock rise. Henry Schein beats quarterly profit estimates on stable dental market
• Positive Sentiment: Robert W. Baird upgraded HSIC, reflecting increased analyst confidence in growth/valuation after results. Upgrades can support further upside as they attract buy-side attention. Henry Schein (NASDAQ:HSIC) Upgraded at Robert W. Baird
• Positive Sentiment: Leerink Partners published a bullish note forecasting strong price appreciation, adding to analyst-driven buying pressure. Leerink Partners Forecasts Strong Price Appreciation for Henry Schein (NASDAQ:HSIC) Stock
• Positive Sentiment: Market reaction to the beat pushed HSIC to a new 12‑month high, signaling momentum traders and momentum-based funds may add exposure. Henry Schein (NASDAQ:HSIC) Hits New 12-Month High on Earnings Beat
• Neutral Sentiment: A Yahoo/Finance piece notes analysts are re‑assessing HSIC’s growth profile and valuation — useful context but not an immediate directional catalyst. How Henry Schein (HSIC) Story Is Shifting As Analysts Reassess Growth And Valuation
• Neutral Sentiment: Short‑interest data shows an anomalous report (0 shares / NaN change), which appears to be a reporting/data error and is unlikely to meaningfully affect near‑term trading.
• Negative Sentiment: CEO Stanley M. Bergman sold sizable blocks of stock on Feb. 26–27 (combined sale proceeds ~ $4.0M+), which can be perceived negatively by some investors as profit‑taking or reduced insider conviction. SEC filing: Insider sale filing

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.